Antimicrobial Agents — MCQs

Antimicrobial Agents Indian Medical PG Practice Questions and MCQs

Question 801: Telaprevir is used in the treatment of which condition?

A. Acute hepatitis B
B. Acute hepatitis C
C. Chronic hepatitis B
D. Chronic hepatitis C (Correct Answer)

Explanation: **Explanation:** **Telaprevir** is a first-generation **NS3/4A protease inhibitor**. Its mechanism of action involves binding to the active site of the HCV protease enzyme, which is essential for the cleavage of the viral polyprotein into functional proteins required for viral replication. 1. **Why Option D is Correct:** Telaprevir was specifically developed and FDA-approved for the treatment of **Chronic Hepatitis C (Genotype 1)**. It is typically used in combination with Peginterferon-alfa and Ribavirin (triple therapy) to increase the Sustained Virologic Response (SVR) rates compared to dual therapy alone. 2. **Why Other Options are Incorrect:** * **Options A & B (Acute Hepatitis):** Acute hepatitis B and C are generally managed supportively. Antiviral therapy is rarely indicated in the acute phase unless there is fulminant liver failure. Protease inhibitors like Telaprevir are specifically indicated for the chronic, replicative stage of HCV. * **Option C (Chronic Hepatitis B):** Hepatitis B is a DNA virus, whereas Hepatitis C is an RNA virus. The NS3/4A protease is unique to the Hepatitis C virus. Chronic HBV is treated with Reverse Transcriptase Inhibitors (e.g., Tenofovir, Entecavir) or Interferon-alfa. **High-Yield Clinical Pearls for NEET-PG:** * **Class:** NS3/4A Protease Inhibitors (Suffix: **"-previr"**; e.g., Telaprevir, Boceprevir, Simeprevir). * **Side Effects:** A major limiting side effect of Telaprevir is a **severe pruritic rash** (which can progress to Stevens-Johnson Syndrome) and **anemia**. * **Drug Interactions:** It is a potent inhibitor of **CYP3A4**, leading to numerous drug-drug interactions. * **Evolution of Therapy:** While high-yield for exams, Telaprevir has largely been replaced in clinical practice by newer Direct-Acting Antivirals (DAAs) like Sofosbuvir due to better safety profiles.

Question 802: Which of the following is NOT a macrolide antibiotic?

A. Erythromycin
B. Roxithromycin
C. Neomycin (Correct Answer)
D. Clarithromycin

Explanation: **Explanation:** The correct answer is **Neomycin** because it belongs to the **Aminoglycoside** class of antibiotics, not the Macrolide class. **1. Why Neomycin is the correct answer:** Neomycin is an aminoglycoside (along with Streptomycin, Gentamicin, and Amikacin). These drugs work by irreversibly binding to the **30S ribosomal subunit**, inhibiting bacterial protein synthesis. Clinically, Neomycin is highly nephrotoxic and ototoxic, which limits its use to topical applications (e.g., skin ointments) or oral administration for "bowel preparation" before surgery (as it is not absorbed systemically). **2. Why the other options are Macrolides:** * **Erythromycin:** The prototype natural macrolide derived from *Saccharopolyspora erythraea*. * **Roxithromycin & Clarithromycin:** These are semi-synthetic derivatives of erythromycin. They offer better acid stability, superior oral absorption, and a broader spectrum of activity. * **Mechanism of Action:** All macrolides work by binding to the **50S ribosomal subunit**, specifically inhibiting the translocation step of protein synthesis. **High-Yield NEET-PG Pearls:** * **Mnemonic for Macrolides:** Remember **"ACE"** (Azithromycin, Clarithromycin, Erythromycin). * **Drug of Choice:** Macrolides are the first-line treatment for *Atypical pneumonia* (Mycoplasma, Legionella) and *Chancroid*. * **Side Effects:** Erythromycin is a **Motilin agonist**, often causing GI upset/diarrhea. It is also a potent **CYP3A4 inhibitor**, leading to numerous drug interactions (unlike Azithromycin). * **Aminoglycoside Rule:** Neomycin is the most toxic aminoglycoside; **Streptomycin** is the least nephrotoxic.

Question 803: Nevirapine is classified as which of the following?

A. Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) (Correct Answer)
B. Protease Inhibitor (PI)
C. Nucleoside Reverse Transcriptase Inhibitor (NRTI)
D. Entry Inhibitor

Explanation: **Explanation:** **Nevirapine** is a first-generation **Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)**. Unlike NRTIs, which are competitive inhibitors that mimic natural nucleotides, NNRTIs act as **non-competitive inhibitors**. They bind directly to a specific hydrophobic pocket on the HIV-1 Reverse Transcriptase enzyme (near but not at the active site), causing a conformational change that halts DNA synthesis. **Analysis of Options:** * **Option A (Correct):** Nevirapine, Efavirenz, and Delavirdine are the classic first-generation NNRTIs. * **Option B (Incorrect):** Protease Inhibitors (e.g., Ritonavir, Lopinavir) inhibit the viral protease enzyme, preventing the cleavage of polyproteins into functional units, thus preventing viral maturation. * **Option C (Incorrect):** NRTIs (e.g., Zidovudine, Tenofovir, Abacavir) are prodrugs that require intracellular phosphorylation to compete with natural nucleotides for incorporation into the viral DNA chain, causing chain termination. * **Option D (Incorrect):** Entry Inhibitors include Fusion Inhibitors (Enfuvirtide) and CCR5 Antagonists (Maraviroc), which prevent the virus from entering the host CD4 cell. **High-Yield Clinical Pearls for NEET-PG:** 1. **Metabolism:** Nevirapine is a potent **inducer of CYP3A4** enzymes, leading to significant drug-drug interactions. 2. **Side Effects:** The most characteristic side effects are **maculopapular rash** (can progress to Stevens-Johnson Syndrome) and **hepatotoxicity**. 3. **Vertical Transmission:** Historically, a single dose of Nevirapine was given to the mother at the onset of labor and to the neonate to prevent mother-to-child transmission (MTCT). 4. **Resistance:** NNRTIs have a low genetic barrier; a single mutation (K103N) can lead to high-level resistance.

Question 804: Which mechanism is responsible for tetracycline resistance?

A. Drug efflux mechanism (Correct Answer)
B. Development of inactivating enzymes
C. DNA methylation
D. Cell wall alteration

Explanation: **Explanation:** Tetracyclines are bacteriostatic antibiotics that inhibit protein synthesis by binding to the **30S ribosomal subunit**. Resistance to this class is widespread and occurs primarily through three mechanisms, with **drug efflux** being the most clinically significant. 1. **Why Option A is Correct:** The most common mechanism of resistance is the acquisition of **efflux pumps** (encoded by *tet* genes, e.g., *tetA*). These energy-dependent pumps actively transport the drug out of the bacterial cell, preventing it from reaching therapeutic concentrations at the ribosome. Another major mechanism is **ribosomal protection**, where proteins (like *TetM*) displace the drug from its binding site. 2. **Why Options B, C, and D are Incorrect:** * **Inactivating enzymes (B):** While enzymatic inactivation (e.g., acetylation) is the hallmark of **Aminoglycoside** resistance, it is rare for tetracyclines. * **DNA methylation (C):** This is a classic mechanism for **Macrolide** (Erythromycin) resistance, where the 50S ribosomal RNA is methylated to prevent drug binding. * **Cell wall alteration (D):** This is typical for **Vancomycin** (D-Ala-D-Lac substitution) or **Beta-lactams** (PBP alterations), but not tetracyclines, which act intracellularly. **High-Yield Clinical Pearls for NEET-PG:** * **Tigecycline:** A glycylcycline designed to overcome efflux-mediated resistance; however, it is still susceptible to the **Proteus** and **Pseudomonas** efflux systems (intrinsic resistance). * **Adverse Effects:** Phototoxicity, enamel hypoplasia (contraindicated in pregnancy/children <8 years), and Fanconi syndrome (expired tetracyclines). * **Doxycycline:** The tetracycline of choice for renal failure patients as it is excreted primarily via bile.

Question 805: All of the following drugs are primarily bacteriostatic except?

A. Sulphonamide
B. Chloramphenicol
C. Ethambutol
D. Rifampicin (Correct Answer)

Explanation: ### Explanation The classification of antimicrobial agents into **bacteriostatic** (inhibiting growth) and **bactericidal** (killing bacteria) is a fundamental concept in pharmacology. **1. Why Rifampicin is the Correct Answer:** **Rifampicin** is a potent **bactericidal** drug. It works by inhibiting the DNA-dependent RNA polymerase enzyme, thereby preventing transcription (mRNA synthesis). In the context of tuberculosis treatment, it is highly effective against both rapidly dividing and intermittently metabolizing bacilli (persisters). Its ability to directly cause cell death makes it the exception in this list. **2. Analysis of Incorrect Options:** * **Sulphonamides:** These are **bacteriostatic** agents. They act as structural analogs of PABA, competitively inhibiting the enzyme dihydropteroate synthase in the folic acid synthesis pathway. (Note: When combined with Trimethoprim as Co-trimoxazole, the effect becomes bactericidal). * **Chloramphenicol:** This is a **bacteriostatic** protein synthesis inhibitor that binds to the 50S ribosomal subunit. While it can be bactericidal against specific organisms like *H. influenzae* or *S. pneumoniae*, it is primarily classified as bacteriostatic. * **Ethambutol:** This is the only **bacteriostatic** first-line anti-tubercular drug (at standard doses). It inhibits arabinosyl transferase, interfering with cell wall synthesis. **3. NEET-PG High-Yield Pearls:** * **Mnemonic for Bactericidal Drugs:** "**V**ery **F**inely **P**enilled **A**minoglycosides **Q**uickly **R**elieve **B**acterial **M**enace" (**V**ancomycin, **F**luoroquinolones, **P**enicillins/Cephalosporins, **A**minoglycosides, **Q**uinolones, **R**ifampicin, **B**acitracin, **M**etronidazole). * **Exception Rule:** Most protein synthesis inhibitors are bacteriostatic (e.g., Tetracyclines, Macrolides), **except Aminoglycosides**, which are bactericidal. * **Clinical Note:** Bacteriostatic drugs rely on the host's immune system to clear the infection; therefore, bactericidal drugs are preferred in immunocompromised patients or for treating endocarditis and meningitis.

Question 806: Which class of antiretroviral drug is used for starting treatment for HIV infection?

A. Protease inhibitors
B. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (Correct Answer)
C. Fusion inhibitors
D. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Explanation: ### Explanation The standard of care for initiating treatment in a treatment-naive HIV patient is **Highly Active Antiretroviral Therapy (HAART)**. According to current WHO and NACO guidelines, the preferred first-line regimen consists of a **"backbone" of two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)** combined with a third drug from another class (typically an Integrase Strand Transfer Inhibitor like Dolutegravir). **Why NRTIs are the correct choice:** NRTIs (e.g., Tenofovir, Lamivudine, Abacavir) act as competitive inhibitors of the viral enzyme Reverse Transcriptase. They are structural analogs of native nucleosides; once phosphorylated, they incorporate into the growing viral DNA chain, causing **obligate chain termination**. Their established efficacy, predictable pharmacokinetics, and role as the foundational "backbone" make them essential for starting treatment. **Analysis of Incorrect Options:** * **Protease Inhibitors (A):** (e.g., Ritonavir, Atazanavir) These prevent the cleavage of gag-pol polyproteins. While potent, they are generally reserved for second-line regimens due to metabolic side effects (dyslipidemia, insulin resistance) and high pill burden. * **Fusion Inhibitors (C):** (e.g., Enfuvirtide) These block the entry of HIV into the host cell. They are administered subcutaneously and are reserved for salvage therapy in multi-drug resistant HIV. * **NNRTIs (D):** (e.g., Efavirenz, Nevirapine) These bind non-competitively to a pocket near the active site of Reverse Transcriptase. While previously used in first-line therapy, they have a low genetic barrier to resistance and are now secondary to Integrase Inhibitors. **High-Yield Clinical Pearls for NEET-PG:** * **Current Preferred Regimen (NACO):** TLD Regimen (**T**enofovir + **L**amivudine + **D**olutegravir). * **Mnemonic for NRTIs:** "ZDS LATTE" (Zidovudine, Didanosine, Stavudine, Lamivudine, Abacavir, Tenofovir, Telbivudine, Emtricitabine). * **Zidovudine:** Notable for causing bone marrow suppression (anemia/neutropenia) and is used for preventing vertical transmission during labor. * **Tenofovir:** Associated with renal toxicity (Fanconi Syndrome) and decreased bone mineral density.

Question 807: Which drug predisposes to pyloric stenosis in infants?

A. Erythromycin (Correct Answer)
B. Streptomycin
C. Tetracycline
D. Nitrofurantoin

Explanation: **Explanation:** The correct answer is **Erythromycin**. **Why Erythromycin is correct:** Erythromycin, a macrolide antibiotic, is a known risk factor for **Infantile Hypertrophic Pyloric Stenosis (IHPS)**. The underlying mechanism involves its action as a **motilin receptor agonist**. Erythromycin mimics the action of the hormone motilin, which stimulates gastrointestinal motility. In neonates (especially those under 2 weeks of age), excessive stimulation of these receptors leads to strong, uncoordinated contractions of the pyloric antrum, eventually resulting in hypertrophy of the pyloric sphincter and gastric outlet obstruction. This risk is highest with oral erythromycin but has also been associated with maternal use during late pregnancy or breastfeeding. **Why the other options are incorrect:** * **Streptomycin:** An aminoglycoside primarily associated with **ototoxicity** (8th cranial nerve damage) and **nephrotoxicity**. In utero exposure can lead to congenital deafness. * **Tetracycline:** Known for causing **discoloration of teeth** and enamel hypoplasia in children due to its ability to chelate calcium. It also inhibits bone growth. * **Nitrofurantoin:** Primarily associated with **hemolytic anemia** in neonates if used near term, especially in those with G6PD deficiency, but it does not affect the pylorus. **Clinical Pearls for NEET-PG:** * **Azithromycin** also carries a risk of IHPS, though it is statistically lower than Erythromycin. * **Classic Presentation of IHPS:** Non-bilious, projectile vomiting in an infant (3–6 weeks old) with a palpable "olive-shaped" mass in the epigastrium. * **Metabolic Abnormality in IHPS:** Hypochloremic, hypokalemic metabolic alkalosis (due to loss of HCl from vomiting). * **Drug of choice for Gastroparesis:** Erythromycin is sometimes used off-label in adults to stimulate gastric emptying due to its prokinetic properties.

Question 808: Which of the following drugs is LEAST effective as a luminal amoebicide?

A. Metronidazole (Correct Answer)
B. Diloxanide furoate
C. Iodoquinol
D. Paromomycin

Explanation: **Explanation:** The treatment of amoebiasis is categorized into **tissue amoebicides** and **luminal amoebicides**. **1. Why Metronidazole is the correct answer:** Metronidazole (and other nitroimidazoles like Tinidazole) is a highly effective **systemic/tissue amoebicide**. It is rapidly and almost completely absorbed from the small intestine. Consequently, it reaches very low concentrations in the colon (the lumen), making it **ineffective** against luminal cysts. While it is the drug of choice for invasive intestinal amoebiasis and liver abscesses, it must always be followed by a luminal agent to eradicate the colonization. **2. Why the other options are incorrect:** * **Diloxanide furoate (Option B):** It is a classic luminal amoebicide. It is split in the gut into diloxanide, which is not well absorbed, allowing it to reach high concentrations in the colon to kill trophozoites. * **Iodoquinol (Option C):** An 8-hydroxyquinoline that is poorly absorbed from the GI tract, acting directly against trophozoites in the intestinal lumen. * **Paromomycin (Option D):** An aminoglycoside antibiotic that is not absorbed from the gut. It is highly effective against luminal forms and is often the preferred agent for asymptomatic cyst passers (especially in pregnancy). **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC) for Asymptomatic Cyst Passers:** Diloxanide furoate or Paromomycin. * **DOC for Hepatic Amoebiasis:** Metronidazole followed by a luminal agent. * **Metronidazole Side Effects:** Metallic taste, Disulfiram-like reaction with alcohol, and neurological toxicity (at high doses). * **Emetine/Dehydroemetine:** These are potent tissue amoebicides but are rarely used now due to cardiotoxicity.

Question 809: What is the most serious side effect of streptomycin?

A. Hepatotoxicity
B. Ototoxicity (Correct Answer)
C. Ocular toxicity
D. Hematological disturbances

Explanation: Streptomycin is an aminoglycoside antibiotic primarily used in the treatment of tuberculosis and certain gram-negative infections. **Why Ototoxicity is the correct answer:** The most serious and characteristic side effects of all aminoglycosides, including streptomycin, are **ototoxicity** and **nephrotoxicity** [2, 3]. Streptomycin specifically targets the **vestibular apparatus** more than the cochlea [2, 3]. It causes irreversible damage to the sensory hair cells in the inner ear [1]. Clinical manifestations include vertigo, loss of balance, and ataxia. While nephrotoxicity is also a concern, permanent hearing loss or vestibular dysfunction is considered the most debilitating "serious" side effect associated with this specific drug [3]. **Analysis of Incorrect Options:** * **Hepatotoxicity (A):** Streptomycin is not significantly metabolized by the liver and is excreted unchanged by the kidneys; therefore, it is not typically associated with liver damage (unlike other anti-TB drugs like Isoniazid or Rifampicin). * **Ocular toxicity (C):** This is a classic side effect of **Ethambutol** (optic neuritis), not streptomycin. * **Hematological disturbances (D):** While rare hypersensitivity reactions can occur, streptomycin is not known for causing significant bone marrow suppression or blood dyscrasias. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Inhibits bacterial protein synthesis by binding to the **30S ribosomal subunit**. * **Pregnancy:** Streptomycin is **teratogenic** (Category D) as it can cause permanent bilateral deafness in the fetus. * **Resistance:** It is the only first-line anti-TB drug that must be administered via **intramuscular injection** and is associated with rapid development of resistance if used alone. * **Neuromuscular Blockade:** Aminoglycosides can aggravate Myasthenia Gravis by interfering with acetylcholine release.

Question 810: Which of the following statements regarding amantadine and rimantadine is false?

A. Rimantadine is 4-10 times more active than amantadine.
B. Combination of amantadine and rimantadine are effective on Influenza B. (Correct Answer)
C. Both act by inhibiting an early step in viral replication.
D. They are effective against influenza A H1N1 if treatment is initiated within 2 days of the onset of symptoms.

Explanation: ### Explanation **Why Option B is False (The Correct Answer):** Amantadine and rimantadine are **M2 ion channel blockers**. The M2 protein is essential for the "uncoating" process of the virus. Crucially, this M2 protein is **only present in Influenza A**. Influenza B viruses lack the M2 protein (they possess a different protein called BM2, which is not inhibited by these drugs). Therefore, neither amantadine nor rimantadine has any clinical activity against Influenza B. **Analysis of Other Options:** * **Option A:** Rimantadine is structurally a methylated derivative of amantadine. In vitro studies and clinical trials demonstrate that it is significantly more potent (approximately 4–10 times) than amantadine. * **Option C:** Both drugs inhibit the **early step of viral replication**, specifically the uncoating of the viral RNA within the host cell. By blocking the M2 ion channel, they prevent the acidification of the viral interior, which is necessary for the release of the viral genome. * **Option D:** While widespread resistance has limited their current use, these drugs are historically effective against Influenza A (including H1N1) if administered within **48 hours** of symptom onset. Early initiation is critical to reduce the duration and severity of the illness. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** M2 Ion Channel Blockers → Inhibit Uncoating. * **Spectrum:** Only Influenza A (Not B). * **Side Effects:** Amantadine is known for CNS side effects (insomnia, dizziness) and **Livedo Reticularis** (mottled skin discoloration). * **Other Uses:** Amantadine is also used in **Parkinsonism** because it increases dopamine release and inhibits its reuptake. * **Resistance:** Most current strains of H1N1 and H3N2 are now resistant; **Oseltamivir** (Neuraminidase inhibitor) is the current drug of choice.

Practice by Chapter

Beta-Lactam Antibiotics

Practice Questions

Aminoglycosides

Practice Questions

Macrolides and Ketolides

Practice Questions

Tetracyclines

Practice Questions

Quinolones

Practice Questions

Sulfonamides and Trimethoprim

Practice Questions

Antimycobacterial Drugs

Practice Questions

Antifungal Agents

Practice Questions

Antiviral Drugs

Practice Questions

Antiparasitic Agents

Practice Questions

Principles of Antimicrobial Selection

Practice Questions

Antimicrobial Resistance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free